Navigation Links
Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
Date:7/2/2012

CRANBURY, N.J., July 2, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that it has entered into a definitive securities agreement and priced a private placement of 3,873,000 shares of its common stock, Series A warrants to purchase 31,988,151 shares of its common stock, and Series B warrants to purchase 35,488,380 shares of its common stock.  Funds under the management of QVT Financial LP have agreed to pay $0.50 for each share of common stock and $0.49 for each Series A warrant and each Series B warrant, resulting in gross proceeds to Palatin of $35,000,000, with net proceeds, after deducting estimated offering expenses, of approximately $34,500,000.

The private placement is expected to close on or about July 5, 2012, subject to customary closing conditions.

Palatin intends to use the proceeds from this offering for general corporate purposes and working capital, including its clinical trial program with bremelanotide for female sexual dysfunction, preclinical and clinical development of its melanocortin receptor-1 peptide program, preclinical and clinical development of its PL-3994 program and preclinical and clinical development of other portfolio products.

Both Series A and Series B warrants are exercisable at an initial exercise price of $0.01 per share.  The Series A warrants are exercisable immediately upon issuance and expire on the tenth anniversary of the date of issuance.  The Series B warrants are also exercisable immediately upon issuance, but only if Palatin's stockholders increase the number of its authorized shares of common stock, and expire on the tenth anniversary of the date of the increase in the number of authorized shares.  Both the Series A warrants and the Series B warrants are subject to limitation on exercise if the holder and its affiliates would beneficially own more than 9.99% of the total number of Palatin's shares of common stock following such exercise.
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
9. Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on December 1st
10. Animal Biotechnology - Technologies, Markets and Companies
11. Gene Therapy - Technologies, Markets and Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 Cynvenio, a ... management through the genomic analysis of tumor cells in ... Finder™, a web-based cancer decision support application powered by ... with Cynvenio’s ClearID™ genomic test, Therapy Finder will provide ...
(Date:1/15/2014)... 15, 2014 A study has been launched ... Formula 1 track could help to tackle the problem of ... Stowhealth (a GP surgery based in Stowmarket) and academics at ... Telemetry technology, which is inspired by equipment used ...
(Date:1/15/2014)... DTS Language Services, Inc . is ... for Life Science organizations who need document translations. Clients ... of their documents in advance with a selection of nearly ... translations, often a critical factor in clinical and scientific fields, ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... For a successful bioscience company there are many moving ... knowledgeable workforce to suppliers and market access, each of ... today,s modern scientific challenges. Yet, leveraging these solutions in ... R&D are high. Complexity in the supply chain can ...
... 2011 NeoStem, Inc. ("NeoStem" or the "Company") (NYSE ... with product and service revenues, global research and development ... U.S. adult stem cells, China adult stem cells, and ... today announced steps forward in their partnership designed to ...
... June 16, 2011 /PRNewswire-Asia/ -- WuXi AppTec announced today that ... Outsourcing Enterprises in China for 2011 by China,s Ministry of ... Service Outsourcing Cooperation Conference, held in Nanjing on June 10, ... WuXi AppTec, was named a Top Ten Contributor to China,s ...
Cached Biology Technology:Ohio's Bioscience Industry Thrives With World-Class Industry Collaboration 2Ohio's Bioscience Industry Thrives With World-Class Industry Collaboration 3Ohio's Bioscience Industry Thrives With World-Class Industry Collaboration 4The Pontifical Council for Culture and NeoStem Announce Steps Forward in their Partnership to Advance Adult Stem Cell Research 2The Pontifical Council for Culture and NeoStem Announce Steps Forward in their Partnership to Advance Adult Stem Cell Research 3The Pontifical Council for Culture and NeoStem Announce Steps Forward in their Partnership to Advance Adult Stem Cell Research 4The Pontifical Council for Culture and NeoStem Announce Steps Forward in their Partnership to Advance Adult Stem Cell Research 5The Pontifical Council for Culture and NeoStem Announce Steps Forward in their Partnership to Advance Adult Stem Cell Research 6The Pontifical Council for Culture and NeoStem Announce Steps Forward in their Partnership to Advance Adult Stem Cell Research 7
(Date:4/17/2014)... Australian National University (ANU), have developed a new ... variability over the past 5.3 million years., The ... surrounding ice ages over the past two million ... carbon dioxide levels, global temperatures and sea levels., ... (UoS) and the National Oceanography Centre (NOC) in ...
(Date:4/17/2014)... of our ideas about domestication derive from Charles ... by British animal-breeding practices during the 19th century, ... improvement. , It is from Darwin that ... of captive animals from wild species and total ... But animal management in this industrial setting has ...
(Date:4/16/2014)... in museum collections two new species of yellow-shouldered bats have been ... The Field Museum of Natural History and described in the open ... to the genus Sturnira are part of a recent ... the third one still waiting to be officially announced. , Up ...
Breaking Biology News(10 mins):Ancient sea-levels give new clues on ice ages 2The story of animal domestication retold 2The story of animal domestication retold 3The story of animal domestication retold 4Two new species of yellow-shouldered bats endemic to the Neotropics 2
... Scientists and engineers from around the world will convene ... discuss recent advances in optics and photonics -- the ... -- affecting renewable energy and environmental research. Journalists ... Photonics Congress: Renewable Energy & the Environment, which will ...
... rats, European researchers have proved that eating strawberries reduces ... mucous membrane. Published in the open access journal Plos ... of stomach ulcers. A team of Italian, Serbian ... strawberries have in a mammal stomach that has been ...
... brain protein that regulates gene expression may play a role ... disabling psychiatric disease. As reported in the latest issue of ... for Bipolar Disorders, levels of SP4 (specificity protein 4) were ... samples from patients with bipolar disorder. The study suggests that ...
Cached Biology News:Space debris, more efficient LEDs, and thinner, cheaper solar cells 2Space debris, more efficient LEDs, and thinner, cheaper solar cells 3Space debris, more efficient LEDs, and thinner, cheaper solar cells 4Space debris, more efficient LEDs, and thinner, cheaper solar cells 5Strawberries protect the stomach from alcohol 2Gene regulatory protein is reduced in bipolar disorder 2Gene regulatory protein is reduced in bipolar disorder 3
... monoclonal antibody raised against a partial recombinant IFNA2. ... a.a.) partial recombinant protein is produced in E. ... 8 IU/ mg. OMIM: ... Lot Number: MM951100564 MA ...
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
Mouse polyclonal antibody to NR2F2 - nuclear receptor subfamily 2, group F, member 2...
Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...
Biology Products: